Crossject Société Anonyme (FRA:74C)
Germany · Delayed Price · Currency is EUR 2.355
+0.105 (4.67%)
At close: Nov 28, 2025
Crossject Société Anonyme Company Description
Crossject Société Anonyme develops needle-free injection systems in France.
The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis.
In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures.
The company was incorporated in 2001 and is based in Dijon, France.
Crossject Société Anonyme
| Country | France |
| Founded | 2001 |
| Industry | Surgical and Medical Instruments and Apparatus |
| Employees | 102 |
| CEO | Patrick Alexandre |
Contact Details
Address: 6 Rue Pauline Kergomard Dijon, 21000 France | |
| Phone | 33 3 80 54 98 50 |
| Website | crossject.com |
Stock Details
| Ticker Symbol | 74C |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Patrick Alexandre | Chief Executive Officer |